Every 8-K that Entrada Therapeutics, Inc. (TRDA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TRDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRDA filings page.
Entrada Therapeutics reported second quarter 2026 results and outlined multiple upcoming clinical milestones across its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. Cash, cash equivalents and marketable securities were $223.0 million as of June 30, 2026, versus $295.7 million as of December 31, 2025, and the company expects this to fund operations into the third quarter of 2027.
For Q2 2026, collaboration revenue was $0.9 million, R&D expenses were $35.4 million, G&A expenses were $10.5 million, and net loss was $42.8 million, or $1.01 per share. The company highlighted progress in its ELEVATE-44-201, ELEVATE-45-201 and ELEVATE-50-201 DMD studies, plans to advance ENTR-601-51, and ongoing development of VX-670 with Vertex, with multiple data readouts expected between the second half of 2026 and the first half of 2027.
Entrada Therapeutics reported the results of its 2026 annual stockholder meeting, held virtually on June 10, 2026. Stockholders approved amendments to the company’s 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan to change the evergreen formulas so that outstanding pre-funded warrants are counted in determining annual share pool increases.
Two Class II directors, Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D., were re-elected to the board. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026. The meeting achieved a quorum, with 33,190,234 of 38,820,616 common shares entitled to vote represented in person or by proxy.
Entrada Therapeutics, Inc. furnished a current report to share an updated corporate presentation with investors, analysts and other stakeholders. The refreshed presentation, dated May 2026, is attached as Exhibit 99.1 and is incorporated by reference in this report.
The disclosure is made under Regulation FD, which is designed to ensure fair and equal access to important company information. The material is expressly described as furnished, not filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings unless specifically referenced.
Entrada Therapeutics reported first quarter 2026 results and detailed encouraging early data for its Duchenne muscular dystrophy programs. Cash, cash equivalents and marketable securities were $254.9 million as of March 31, 2026, and the company expects its cash runway to extend into the third quarter of 2027.
In the Phase 1/2 ELEVATE-44-201 study, Cohort 1 participants receiving ENTR-601-44 at 6 mg/kg showed favorable safety and tolerability, with no serious adverse events or discontinuations and kidney function markers remaining normal. Treated participants had a 2.36% increase in dystrophin over a 4.00% baseline and a 2.31% increase in exon skipping over a 2.66% baseline.
The study also showed a statistically significant improvement in Time to Rise velocity versus placebo, more than three times the minimal clinically important difference, suggesting early functional benefit. Financially, collaboration revenue declined to $0.9 million from $20.6 million a year earlier, while R&D expenses were $33.1 million and net loss widened to $39.7 million, or $0.95 per share.
Entrada Therapeutics reported fourth-quarter and full-year 2025 results that reflect a shift from collaboration-driven revenue to heavier investment in its genetic medicines pipeline. Collaboration revenue fell to $1.3 million in the fourth quarter and $25.4 million for 2025, down from $37.4 million and $210.8 million in 2024, mainly because work under the VX-670 collaboration research plan substantially finished in early 2025.
Research and development spending rose to $142.3 million for 2025, helping drive a full-year net loss of $143.8 million after net income of $65.6 million in 2024. The company ended 2025 with $295.7 million in cash, cash equivalents and marketable securities and expects this to fund operations into the third quarter of 2027. Entrada highlighted progress across multiple Duchenne muscular dystrophy programs, including a positive independent committee recommendation to escalate dosing in the ELEVATE-44-201 study, and outlined clinical data readouts expected throughout 2026.
Entrada Therapeutics reported preliminary cash, cash equivalents and marketable securities of $296 million as of December 31, 2025, and indicated its cash resources are expected to be sufficient into the third quarter of 2027. This estimate is unaudited and may change when the year-end audit is completed.
The company outlined major progress in its RNA-based therapeutics pipeline for neuromuscular and ocular diseases. It completed dosing of Cohort 1 in the global Phase 1/2 multiple ascending dose study of ENTR-601-44 in Duchenne muscular dystrophy and moved into the open-label Phase 2 portion, with first cohort data from ELEVATE-44-201 expected in Q2 2026. The FDA granted Rare Pediatric Disease Designation to ENTR-601-44, regulators in the U.K. authorized a Phase 1/2 study of ENTR-601-50, and Entrada plans additional studies and filings for ENTR-601-45, ENTR-601-50, ENTR-601-51 and ocular candidate ENTR-801 through 2026, alongside continued development of its partnered VX-670 program.
Entrada Therapeutics, Inc. filed a current report describing that it announced financial results for the quarter ended September 30, 2025, along with other corporate updates. These results and updates are provided in a press release dated November 6, 2025, which is included as an exhibit to the report.
The press release is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.